FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200519983> ?p ?o ?g. }

• W4200519983 endingPage "246" @default.
• W4200519983 startingPage "238" @default.
• W4200519983 abstract "Objective Patients with immune-mediated diseases treated with anti-CD20 monoclonal antibodies may have worse coronavirus disease 2019 (COVID-19) outcomes due to impaired humoral immunity, but differences compared with the general population are unknown. Methods We identified patients with immune-mediated diseases who received anti-CD20 monoclonal antibodies within 1 year prior to the index date of polymerase chain reaction–confirmed COVID-19 between January 31, 2020, and January 31, 2021. General population comparators with COVID-19 were matched up 5:1 by age, sex, and polymerase chain reaction date. Unadjusted and multivariable adjusted (for age, race, body mass index, and Charlson Comorbidity Index) hazard ratios (HRs) and 95% confidence intervals (CIs) for hospitalization, mechanical ventilation, and death in recipients of anti-CD20 monoclonal antibodies versus comparators were estimated by using Cox regression. Results We identified 114 cases patients COVID-19 who had received anti-CD20 monoclonal antibodies for immune-mediated diseases (mean age 55 years, 70% female) and 559 matched comparators with COVID-19 (mean age 54 years, 70% female). Patients treated with anti-CD20 monoclonal antibodies had higher mortality (adjusted HR 2.16; 95% CI: 1.03-4.54) than matched comparators. Risks of hospitalization (adjusted HR 0.88; 95% CI: 0.62-1.26) and mechanical ventilation use (adjusted HR 0.82; 95% CI: 0.36-1.87) were similar. Similar trends were seen in analyses according to type of indication (eg, rheumatic or neurologic disease) and duration of anti-CD20 monoclonal antibody use (<1 or ≥1 year) and after patients with interstitial lung disease, those with cancer, and those on glucocorticoids prior to COVID-19 diagnosis were excluded. Conclusion Patients who received anti-CD20 monoclonal antibodies for immune-mediated diseases prior to COVID-19 had higher mortality following COVID-19 than matched comparators, highlighting the urgent need to mitigate excess risks in recipients of anti-CD20 monoclonal antibodies during the ongoing pandemic." @default.
• W4200519983 created "2021-12-31" @default.
• W4200519983 creator A5003092903 @default.
• W4200519983 creator A5004944795 @default.
• W4200519983 creator A5006378101 @default.
• W4200519983 creator A5006664277 @default.
• W4200519983 creator A5015009700 @default.
• W4200519983 creator A5018239396 @default.
• W4200519983 creator A5027786522 @default.
• W4200519983 creator A5047092553 @default.
• W4200519983 creator A5052663273 @default.
• W4200519983 creator A5059557885 @default.
• W4200519983 creator A5062489482 @default.
• W4200519983 creator A5065078602 @default.
• W4200519983 creator A5067100846 @default.
• W4200519983 date "2021-12-10" @default.
• W4200519983 modified "2023-10-16" @default.
• W4200519983 title "Coronavirus Disease 2019 Outcomes Among Recipients of <scp>Anti‐CD20</scp> Monoclonal Antibodies for <scp>Immune‐Mediated</scp> Diseases: A Comparative Cohort Study" @default.
• W4200519983 cites W1504813440 @default.
• W4200519983 cites W2000445173 @default.
• W4200519983 cites W2038981426 @default.
• W4200519983 cites W3024016727 @default.
• W4200519983 cites W3030308448 @default.
• W4200519983 cites W3033192149 @default.
• W4200519983 cites W3039360323 @default.
• W4200519983 cites W3047352944 @default.
• W4200519983 cites W3049048202 @default.
• W4200519983 cites W3080323991 @default.
• W4200519983 cites W3082768564 @default.
• W4200519983 cites W3084879098 @default.
• W4200519983 cites W3087063072 @default.
• W4200519983 cites W3102798166 @default.
• W4200519983 cites W3109910417 @default.
• W4200519983 cites W3111431752 @default.
• W4200519983 cites W3112956657 @default.
• W4200519983 cites W3121831652 @default.
• W4200519983 cites W3124810175 @default.
• W4200519983 cites W3131591676 @default.
• W4200519983 cites W3132798068 @default.
• W4200519983 cites W3135219593 @default.
• W4200519983 cites W3138469897 @default.
• W4200519983 cites W3144879873 @default.
• W4200519983 cites W3162898139 @default.
• W4200519983 cites W3163312867 @default.
• W4200519983 cites W3163785571 @default.
• W4200519983 cites W3164069651 @default.
• W4200519983 cites W3164519882 @default.
• W4200519983 cites W3172513986 @default.
• W4200519983 cites W3197081215 @default.
• W4200519983 doi "https://doi.org/10.1002/acr2.11386" @default.
• W4200519983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34890478" @default.
• W4200519983 hasPublicationYear "2021" @default.
• W4200519983 type Work @default.
• W4200519983 citedByCount "24" @default.
• W4200519983 countsByYear W42005199832022 @default.
• W4200519983 countsByYear W42005199832023 @default.
• W4200519983 crossrefType "journal-article" @default.
• W4200519983 hasAuthorship W4200519983A5003092903 @default.
• W4200519983 hasAuthorship W4200519983A5004944795 @default.
• W4200519983 hasAuthorship W4200519983A5006378101 @default.
• W4200519983 hasAuthorship W4200519983A5006664277 @default.
• W4200519983 hasAuthorship W4200519983A5015009700 @default.
• W4200519983 hasAuthorship W4200519983A5018239396 @default.
• W4200519983 hasAuthorship W4200519983A5027786522 @default.
• W4200519983 hasAuthorship W4200519983A5047092553 @default.
• W4200519983 hasAuthorship W4200519983A5052663273 @default.
• W4200519983 hasAuthorship W4200519983A5059557885 @default.
• W4200519983 hasAuthorship W4200519983A5062489482 @default.
• W4200519983 hasAuthorship W4200519983A5065078602 @default.
• W4200519983 hasAuthorship W4200519983A5067100846 @default.
• W4200519983 hasBestOaLocation W42005199833 @default.
• W4200519983 hasConcept C126322002 @default.
• W4200519983 hasConcept C159654299 @default.
• W4200519983 hasConcept C203014093 @default.
• W4200519983 hasConcept C207103383 @default.
• W4200519983 hasConcept C2777080012 @default.
• W4200519983 hasConcept C2908647359 @default.
• W4200519983 hasConcept C44249647 @default.
• W4200519983 hasConcept C542903549 @default.
• W4200519983 hasConcept C71924100 @default.
• W4200519983 hasConcept C99454951 @default.
• W4200519983 hasConceptScore W4200519983C126322002 @default.
• W4200519983 hasConceptScore W4200519983C159654299 @default.
• W4200519983 hasConceptScore W4200519983C203014093 @default.
• W4200519983 hasConceptScore W4200519983C207103383 @default.
• W4200519983 hasConceptScore W4200519983C2777080012 @default.
• W4200519983 hasConceptScore W4200519983C2908647359 @default.
• W4200519983 hasConceptScore W4200519983C44249647 @default.
• W4200519983 hasConceptScore W4200519983C542903549 @default.
• W4200519983 hasConceptScore W4200519983C71924100 @default.
• W4200519983 hasConceptScore W4200519983C99454951 @default.
• W4200519983 hasFunder F4320332705 @default.
• W4200519983 hasFunder F4320337362 @default.
• W4200519983 hasIssue "3" @default.
• W4200519983 hasLocation W42005199831 @default.
• W4200519983 hasLocation W42005199832 @default.
• W4200519983 hasLocation W42005199833 @default.
• W4200519983 hasLocation W42005199834 @default.

• next